Hepatitis C

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Glecaprevir/Pibrentasvir Is Safe, Efficacious for HCV/HIV-1 Coinfection

Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.

Project ECHO: Educational Support to Improve Hepatitis Care

Project ECHO: Educational Support to Improve Hepatitis Care

By

Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

Healthcare Program Obtains 93% of Prior Authorization Approvals for HCV Medications

By

The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

By

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-Acting Antivirals Improve Liver Transplant Survival

Direct-acting antivirals improved the survival of patients undergoing liver transplantation for HCV-related liver disease.

HCV treatment with direct antiviral agents improves carotid atherosclerosis

HCV treatment with direct antiviral agents improves carotid atherosclerosis

By

Hepatitis C virus eradication by direct antiviral agents improves carotid atherosclerosis in patients with advanced fibrosis and compensated cirrhosis.

Hepatitis C treatment benefits lupus patients

Hepatitis C treatment benefits lupus patients

Immunosuppressive agents do not increase the risk of HCV flares in anti-HCV-positive lupus patients.

Once-daily daclatasvir plus sofosbuvir yields high SVR in HCV

Once-daily daclatasvir plus sofosbuvir yields high SVR in HCV

By

Daclatasvir plus sofosbuvir demonstrated a sustained virological response in 98% of patients with genotype 1 hepatitis C infection.

Does extensive hepatitis C screening help or harm?

Does extensive hepatitis C screening help or harm?

By

The risk-benefit profile of more widespread hepatitis C screening is not sufficiently understood, researchers suggest.

Hepatitis C does not cause mental impairment in HIV patients

Hepatitis C does not cause mental impairment in HIV patients

Researchers have eliminated hepatitis C as the cause of impaired mental function in HIV patients.

FDA approves combination simeprevir and sofosbuvir for HCV treatment

FDA approves combination simeprevir and sofosbuvir for HCV treatment

Combination simeprevir and sofosbuvir has been approved by the FDA for treatment of chronic genotype 1 hepatitis C.

Focus shifts from HCV to fatty liver disease

Focus shifts from HCV to fatty liver disease

Fatty liver disease and other topics gained traction at the AASLD Annual Meeting as HCV therapy research plateaus.

Sign Up for Free e-newsletters